Naina Bhasin Joins Hamner Institute as Director of Business and Technology Development
Naina Bhasin has joined the Hamner Institute for Health Sciences in Research Triangle Park, NC, as its director of business and technology development, the News & Observer of Raleigh, NC, reported.
Bhasin will manage partnerships between Hamner and education, government and private business partners involved in public health and pharmaceutical research.
She also will help develop Hamner’s new Accelerator for Translational BioScience, which brings Hamner resources to emerging companies and universities.
Steve Mandell, IP Lawyer and Founder of BIO IT Coalition, Dies at 60
Steve Mandell, an intellectual property lawyer specializing in business development and the founder of an organization to promote biotechnology and information technology development in the Washington, DC, area, died April 15 of complications from esophageal cancer at his home in Virginia’s Arlington County, the Washington Post reported. He was 60.
Mandell in 2001 founded the BIO IT Coalition, which promotes the development of biological and information technology businesses in the Washington region. A tribute to Mandell was featured at the coalition's most recent annual conference on April 23.
From 2000 until his retirement last December, Mandell had been a partner with the law firm Pepper Hamilton in Washington, leading its entrepreneurial enterprises group and serving as counsel for entrepreneurial life science companies and other businesses. In 1984, he formed the Mandell Law Firm, which specialized in business and intellectual property law.
Two years earlier, Mandell arrived in the Washington region as an executive with MCI Communications, playing an instrumental role in developing the telecom’s early cell phone business. He joined MCI in its Dallas offices after serving as a product-planning executive for Xerox.
Mandell also hosted "Tomorrow's Business," a weekly radio talk show about business and the economy, on WBIS-AM from 1996 until December 2007.
Mandell was born in Philadelphia and served in the Army Quartermaster Corps. He graduated from Drexel University in Philadelphia in 1970, received a master's degree in business administration from Temple University in 1972, and a law degree in 1977 from Southern Methodist University's law school in Dallas.
Survivors include his wife of 38 years, Eileen Mandell of Arlington; three sons, Joshua Mandell of Rock Hill, Mo., Adam Mandell of Falls Church, and Michael Mandell of Arlington; two brothers, Herbert Mandell of Wyncote, Pa., and Paul Mandell of Vienna; a sister, Ruth Ann Mandell of Cherry Hill, N.J.; and two grandsons.
Robert Millman, Elizabeth Stoner Join MPM Senior Investment Team
Robert Millman and Elizabeth Stoner have joined MPM Capital as executive partners. Both are based in the life sciences venture capital firm’s Boston office.
Millman most recently served as chief intellectual property counsel for Alnylam Pharmaceuticals, where he developed the company’s intellectual property portfolio in RNAi therapeutics. Prior to Alnylam, for three years he served in similar positions at Infinity Pharmaceuticals, a company focused on small molecule discovery; and at Celera Genomics, where he developed and implemented an IP protection plan from 1999 to 2002, during the race to sequence the human genome.
Earlier, Millman served as patent counsel at Millennium Pharmaceuticals, as an associate with the law firm Morrison and Foerster, and as a patent agent/specialist at Sterne, Kessler Goldstein and Fox. Millman received his JD degree from the Washington College of Law at The American University, an MSci degree in genetics from Washington State University, and a BSci degree in biochemistry from the University of California, Riverside.
Stoner joined MPM following a 22-year career at Merck Research Laboratories. At the time of her retirement from Merck, Stoner was senior vice president of global clinical development operations with responsibility for the company’s clinical development activities in more than 40 countries. She also oversaw the clinical development activities of Merck’s Japanese partner Banyu, led the clinical development for the Merck/Schering-Plough Joint Venture for Zetia/Vytorin, and played a critical leadership role in Merck’s efforts to transform its worldwide clinical development operations.
Earlier in her career at Merck, Stoner led from inception the clinical development program for the prostate disease treatment Proscar. As endocrine therapeutic head, Stoner’s responsibilities included all steroid and lipid metabolism, as well as the growth hormone secretagogue, and clinical research programs.
Before joining Merck, Stoner was an assistant professor of pediatrics at Cornell University Medical College. Stoner received a BSci in chemistry from Ottawa (Kans.) University, a MSci degree in chemistry from the State University of New York at Stony Brook, and an MD degree from Albert Einstein College of Medicine.